Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.

Colony stimulating factor 1 (CSF-1) recruits tumor-infiltrating myeloid cells (TIM) that suppress tumor immunity, including M2 macrophages and myeloid-derived suppressor cells (MDSC). The CSF-1 receptor (CSF-1R) is a tyrosine kinase that is targetable by small molecule inhibitors such as PLX3397. In this study, we used a syngeneic mouse model of BRAF(V600E)-driven melanoma to evaluate the ability of PLX3397 to improve the efficacy of adoptive cell therapy (ACT). In this model, we found that combined treatment produced superior antitumor responses compared with single treatments. In mice receiving the combined treatment, a dramatic reduction of TIMs and a skewing of MHCII(low) to MHCII(hi) macrophages were observed. Furthermore, mice receiving the combined treatment exhibited an increase in tumor-infiltrating lymphocytes (TIL) and T cells, as revealed by real-time imaging in vivo. In support of these observations, TILs from these mice released higher levels of IFN-γ. In conclusion, CSF-1R blockade with PLX3397 improved the efficacy of ACT immunotherapy by inhibiting the intratumoral accumulation of immunosuppressive macrophages.

[1]  T. Graeber,et al.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. , 2013, The Journal of clinical investigation.

[2]  A. Ribas,et al.  Targeting oncogenic drivers and the immune system in melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Mohammad,et al.  c-Fms Signaling Mediates Neurofibromatosis Type-1 Osteoclast Gain-In-Functions , 2012, PloS one.

[4]  J. Kirkwood,et al.  Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-&agr; or TLR-9 Agonist and GM-CSF With Peptide Vaccination , 2012, Journal of immunotherapy.

[5]  V. Nacu,et al.  PSTPIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts. , 2012, Blood.

[6]  T. Graeber,et al.  BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. , 2012, Cancer research.

[7]  S. Rosenberg,et al.  Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma , 2012, Clinical Cancer Research.

[8]  Upendra K. Kar,et al.  Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer , 2012, PloS one.

[9]  N. Restifo,et al.  Cellular constituents of immune escape within the tumor microenvironment. , 2012, Cancer research.

[10]  J. Segall,et al.  Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling , 2012, Molecular medicine.

[11]  Ruchir R. Shah,et al.  Abstract 3928: Inhibition of the ubiquitin proteasome system differentially regulates glucocorticoid receptor-mediated transcriptional processes , 2012 .

[12]  L. Hesson,et al.  Abstract 3125: Relative distribution of folate species is associated with global DNA methylation in human colorectal mucosa , 2012 .

[13]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[14]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[15]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[16]  L. Williams,et al.  Functional overlap but differential expression of CSF‐1 and IL‐34 in their CSF‐1 receptor‐mediated regulation of myeloid cells , 2010, Journal of leukocyte biology.

[17]  R. Jain,et al.  Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. , 2010, Cancer research.

[18]  B. Comin-Anduix,et al.  Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses , 2010, Proceedings of the National Academy of Sciences.

[19]  H. Vogel,et al.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. , 2010, The Journal of clinical investigation.

[20]  A. Lusis,et al.  Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. , 2010, Blood.

[21]  F. Marincola,et al.  Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. , 2009, Cancer research.

[22]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[23]  K. Pienta,et al.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. , 2009, Cancer research.

[24]  J. Talmadge,et al.  Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. , 2008, Blood.

[25]  L. Williams,et al.  Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome , 2008, Science.

[26]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[27]  J. Pollard,et al.  Conditional deletion of the colony stimulating factor‐1 receptor (c‐fms proto‐oncogene) in mice , 2006, Genesis.

[28]  R. Russell,et al.  Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. , 2002 .

[29]  R. Russell,et al.  Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. , 2002, Blood.